

### PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 75149

**Title:** Incretin based therapy and pancreatic cancer: Realising the reality

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05387405 Position: Peer Reviewer

Academic degree: MSc, PhD

**Professional title:** Research Scientist

**Reviewer's Country/Territory:** Hungary

**Author's Country/Territory:** India

Manuscript submission date: 2022-01-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-17 18:10

Reviewer performed review: 2022-01-18 11:14

**Review time:** 17 Hours

Scientific quality	[ Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous



# Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

The mini review about incretins and their relation to pancreatic cancer is well written and easy to follow. There are a few small conjugation problem here and there, therefore, a thourough reading is suggested. Reviewer recommends to add an additional table or paragraph for introduction, where the various incretin mediactions could be listed.



## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 75149

**Title:** Incretin based therapy and pancreatic cancer: Realising the reality

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05566451 Position: Editorial Board Academic degree: PhD

**Professional title:** Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: India

**Manuscript submission date:** 2022-01-17

Reviewer chosen by: AI Technique

**Reviewer accepted review:** 2022-02-02 13:23

Reviewer performed review: 2022-02-04 02:31

**Review time:** 1 Day and 13 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes [ ]No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous



statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

The authors review the existing literature and describe the relationship between incretin-based therapies and PC. They concluded that the risks of incretin-based therapies appear smaller compared to their beneficial pleotropic effects. This content is instructive to clinical practice. The article is reasonable in structure and detailed in content.

Some words are wrong, please read the full text and revise it carefully.



## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 75149

**Title:** Incretin based therapy and pancreatic cancer: Realising the reality

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05573818 Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Chief Doctor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: India

**Manuscript submission date:** 2022-01-17

Reviewer chosen by: AI Technique

**Reviewer accepted review:** 2022-02-01 02:33

Reviewer performed review: 2022-02-04 10:00

**Review time:** 3 Days and 7 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ Y] Major revision [ ] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

**E-mail:** bpgoffice@wjgnet.com **https:**//www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

Comments: This manuscript focused on the inconsistent literature finding about incretin based therapy and pancreatic cancer. Overall, the mini-review was interesting and potential essential on future clinical decision-making. However, there existed some problems need to be solved before publishing. 1. The structure of this mini-review was confused to follow. In my opinion, the benefit and harm of incretin based therapy and pancreatic cancer should be clearly clarified. 2. A graphic explanation should be recommended. 3. The author concluded that "It seems that incretin-based therapies do not increase the risk for PC. Rather, new experimental data have shown some beneficial effects on cancer cells needing further evaluation.". Please discussed is there exist potential elements (For example: History of pancreatitis or gastrointestinal tumors) influence the effect of incretin. 4. Some format errors should be corrected. And added full name in the manuscript when abbreviation used first time.